We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZOLGENSMA (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ZOLGENSMA
Date registered
Evaluation commenced
Decision date
Approval time
199 (255 working days)
Active ingredients
onasemnogene abeparvovec
Registration type
NCE/NBE
Indication
ZOLGENSMA (injection for intravenous infusion) (onasemnogene abeparvovec) is indicated for the treatment of paediatric patients less than 9 months of age with symptomatic or pre-symptomatic spinal muscular atrophy with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene and 1 to 3 copies of the SMN2 gene.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.